Plausible contributory factors encompass both generally applicable elements, such as genetic drift, clonal selection, survival mechanisms, or technical variation35, and breast cancer-specific factors, such as the use of trastuzumab, which induces HER2 internalization, decreasing its detectability via IHC34. This evidence concerns the gene ERBB2 and breast carcinoma.